



PHARMACY AND POISONS BOARD

PUBLIC ALERT

UNREGISTERED AND SUSPECTED SUBSTANDARD HEALTH PRODUCTS

The Pharmacy and Poisons Board ("the Board"), is the National Regulatory Authority (NRA) established under the Pharmacy and Poisons Act, (CAP 244). In implementation of its mandate, the Board conducts market surveillance for the presence of illegal medicinal substances.

During routine Post-Market Surveillance (PMS) activities, the Board identified two health products that are **unregistered and suspected substandard**:

S/N	BRAND NAME	INN NAME	MANUFACTURER NAME	INDICATION
1	Oxaliage	Oxaliplatin 100mg/50ml	Medion Biotech PVT. Ltd, India	Management of cancer
2	Namanheparin	Heparin 25000IU/5ml	Naman Pharma Drugs, India	Treatment and prevention of blood clots


In light of this, the Board strongly cautions the public and healthcare professionals **AGAINST** trading, distribution, wholesaling, retailing, issuing, dispensing, using, or administering this product to patients

Additionally, the Board in collaboration with Government Investigative Agencies will take legal and regulatory actions against individuals involved in placing these unregistered products on the market, in violation of the Pharmacy and Poisons Act (CAP 244).

The Board remains committed to protecting public health and urges both the public and healthcare professionals to remain vigilant. Any suspected cases of sub-standard or falsified medicines or adverse drug reactions following the use of Health Products and Technologies (HPTs) can be reported to the nearest healthcare facility or the Pharmacy and Poisons Board through the following channels:

- Online <https://pv.pharmacyboardkenya.org/users/mpublic>
- USSD code at *271#
- Mobile application: mPvERS both Android & iOS
- Email pv@ppb.go.ke or pms@ppb.go.ke
- Telephone No. 0795743049

Your cooperation is essential in ensuring the safety and quality of HPTs in Kenya.


Dr. F. M. Siyoi
CHIEF EXECUTIVE OFFICER
SG/os

6th January 2025

PHOTO

